- Founded
- 2020
- CEO
- Amir Hefni
- Founders
- Prof. Stuart Forbes
Prof. John Campbell - % Shareholding
- 82%
- Stage
- Pre-clinical
- Number of employees
- 60+
- Extension of £26.6m Series A announced in April 2022
- £10m
Unless stated all financials at 31 December 2023
Resolution is developing macrophage cell therapies to repair inflammatory organ damage.
Syncona co-founded Resolution following a two year collaboration with researchers at the University of Edinburgh and the Scottish National Blood Transfusion Service.
Resolution is developing macrophage cell therapies to repair inflammatory organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury; the company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings.
Investment thesis
- An opportunity to create the leading inflammation-focused macrophage cell therapy business, focusing initially on treatment of liver cirrhosis. The goal is to repair the livers of patients sufficiently to reduce the risk of decompensation. Future opportunity lies in lung and kidney repair in chronic fibrotic disease.
Unmet medical need
- Chronic inflammatory organ damage represents a major burden to patients. If left untreated, liver cirrhosis will often progress to decompensation through significant loss of liver function. Today there are no efficacious treatments to prevent deterioration in the latter stages of the disease, thus leaving costly and burdensome liver transplantation often as the only option.
Market opportunity
-
New diagnoses of liver cirrhosis affect hundreds of individuals per million of population
Syncona team
Edward Hodgkin
Gonzalo Garcia
Lisa Bright
Gwenaelle Pemberton
Resolution Therapeutics leaders and founders
Other pre-clinical portfolio companies
